Cardiologists Use Endovascular Device for Brain Aneurysms to Treat High-Risk Heart Patients

Why It Matters

It provides a safe, rapid treatment for high‑risk coronary aneurysms, expanding therapeutic options and showcasing the value of cross‑specialty innovation in cardiovascular care.

Key Takeaways

• WEB SLS II originally designed for intracranial aneurysms
• First coronary case: 74‑year‑old pre‑valve surgery patient
• Procedure showed no acute complications; aneurysm sealed
• Multidisciplinary team leveraged neuro‑interventional expertise
• May spark flow‑modification devices for coronary aneurysms

Pulse Analysis

Coronary artery aneurysms, particularly saccular lesions, have long posed a therapeutic dilemma because traditional stenting or surgical exclusion can be technically prohibitive and carry heightened risk. These rare anomalies often arise in patients already slated for complex cardiac surgery, leaving clinicians with limited minimally invasive alternatives. The scarcity of dedicated coronary devices forces physicians to balance procedural safety against the need for durable aneurysm exclusion, a gap that has spurred interest in innovative off‑label solutions.

The Mayo Clinic team identified a physiological parallel between bifurcation aneurysms in the brain and saccular aneurysms in the coronary tree, prompting the off‑label use of the WEB SLS II flow disruptor. By deploying the device within the aneurysm sac, blood flow is redirected, promoting thrombosis while preserving flow in adjacent vessels—a principle well‑established in neurointervention. In the inaugural case, the device achieved immediate occlusion, and six‑month computed tomography angiography confirmed persistent closure without residual leak. The procedure required only dual antiplatelet therapy and a brief hospital stay, underscoring its practicality for high‑risk patients.

Beyond the immediate clinical success, this repurposing signals a broader shift toward flow‑modification strategies in interventional cardiology. Device manufacturers may explore dedicated coronary flow disruptors, creating a new market segment that blends neuro‑vascular technology with cardiac applications. Moreover, the collaborative model—melding interventional cardiology, congenital cardiology, and neuro‑interventional radiology—highlights how multidisciplinary expertise can accelerate innovation. Ongoing registries and long‑term safety studies will be essential to validate efficacy, but the early results suggest a promising avenue for patients previously deemed untreatable.